Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia

AIM: To investigate whether the cardiorenal benefits of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin are affected by body mass index (BMI) in type 2 diabetes patients with established cardiovascular (CV) disease, including Asians. METHODS: In this exploratory analysis of the EMPA‐REG...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Qiuhe, Ji, Linong, Mu, Yiming, Zhao, Jiajun, Zinman, Bernard, Wanner, Christoph, George, Jyothis T., Zwiener, Isabella, Ueki, Kohjiro, Yokote, Koutaro, Ogawa, Wataru, Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361954/
https://www.ncbi.nlm.nih.gov/pubmed/33950573
http://dx.doi.org/10.1111/dom.14415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361954/
https://www.ncbi.nlm.nih.gov/pubmed/33950573
http://dx.doi.org/10.1111/dom.14415

Ejemplares similares